Cover Image
市場調查報告書

生物醫藥品:新的製劑、給藥方法 (對抗體、蛋白質的關注)

Biotherapeutics: Novel Formulation and Delivery Approaches (Focus on Antibodies and Proteins)

出版商 ROOTS ANALYSIS 商品編碼 345310
出版日期 內容資訊 英文 301 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物醫藥品:新的製劑、給藥方法 (對抗體、蛋白質的關注) Biotherapeutics: Novel Formulation and Delivery Approaches (Focus on Antibodies and Proteins)
出版日期: 2015年11月10日 內容資訊: 英文 301 Pages
簡介

生物醫藥品,現在在醫藥品產業中是急速成長的市場區隔之一。生物醫藥品 (已經過核准、開發中雙方) 中包含單株抗體、細胞療法、凝血因子、細胞激素、酵素、荷爾蒙及疫苗。

本報告以全球生物醫藥品市場為主題,提供市場概要、市場規模與預測、各傳送形態的市場分析、開發與聯盟/合作趨勢,及主要企業簡介等彙整,為您概述為以下內容。

第1章 序論

第2章 摘要整理

第3章 生物醫藥品:簡介

  • 背景、概要
  • 生物醫藥品為何引人注目?
  • 生物醫藥品的各種層級
  • 從藥物遞輸的進步取得好處的生物醫藥品
  • 抗體療法
  • 藥物遞輸技術類型
  • 新的藥物遞輸技術的需求

第4章 市場概要

  • 本章概要
  • 生物醫藥品的給藥技術 (蛋白質、抗體)
  • 許多技術關注新製劑
  • 技術大部分關注特定的給藥途徑

第5章 主要口服製劑及輸送平台

  • 本章概要
  • 技術授權最常見的聯盟模式
  • Gastrointestinal Permeation Enhancement Technology (GIPET, Merrion Pharmaceuticals)
  • Protein Oral Delivery Technology (POD, Oramed)
  • Multi Matrix System (MMX, Cosmo Pharmaceuticals)
  • Eligen (Emisphere Technologies)
  • RapidMist (Generex Biotechnology)
  • Axcess (Proxima Concepts)

第6章 主要皮下注射製劑及輸送平台

  • 本章概要
  • 技術授權及共同研究為2個一般聯盟模式
  • ENHANZE Technology (Halozyme Therapeutics)
  • Bepo (MedinCell)
  • Medusa (Flamel Technologies)
  • XeriJect (Xeris Pharmaceuticals)
  • BioChaperone (Adocia)
  • Crystalomics Technology (Ajinomoto Althea)
  • TransCon Technology (Ascendis Pharma)

第7章 主要皮膚適用製劑及輸送平台

  • 本章概要
  • 技術授權最常見的協定模式
  • MicroCor Technology (Corium International)
  • MicronJet (NanoPass Technologies)
  • ZP Patch Technology (Zosano Pharma)

第8章 其他製劑、輸送平台

  • 本章概要
  • 產品開發、評估協定偏好的合作形態
  • nanoZYME, poloMAC 及 poxoMAC (NeuroNano Pharma)
  • Β-Eliminative Drug Delivery System (ProLynx)
  • Intravail 及 Aegis Hydrogels (Aegis Therapeutics)
  • PharmFilm Technology (MonoSol Rx)
  • PLEX Platform (PolyPid)
  • Tethadur (pSivida)
  • Phylomer Peptides (Phylogica)
  • Transcend Technology (biOasis)
  • LRP Technology (Angiochem)

第9章 近幾年的聯盟/合作

  • 本章概要
  • 聯盟模式/協定
  • 相關利益者間的協定穩定
  • 產品開發、技術授權為偏好的聯盟形態

第10章 創業投資資金

  • 本章概要
  • 關注生物醫藥品製劑、輸送的資金提供的實例
  • 創業投資資金提供的增加
  • 資金提供的實例:各資金提供類型的區分
  • 主要的技術開發者:各資金提供的實例數的區分
  • 最活躍的VC企業/機關

第11章 市場預測

  • 本章概要
  • 預測手法
  • 整體藥物遞輸技術市場
  • 皮下附註藥物遞輸技術市場
  • 口服藥物遞輸技術市場
  • 皮膚適用藥物遞輸技術市場
  • 其他藥物遞輸技術市場

第12章 SWOT分析

  • 優勢
  • 弱點
  • 機會
  • 威脅

第13章 採訪記錄

第14章 結論

圖表

目錄
Product Code: RA10049

Biopharmaceuticals is currently one of the fastest growing segments in the pharmaceutical industry. They have a vital use in the treatment of chronic diseases and also result in high profit margins for the drug developers. There are several therapeutic areas for which biopharmaceuticals are being investigated; these include oncology, metabolic disorders, viral infections, genetic disorders and immunological disorders. Biotherapeutics (both approved and under investigation) include monoclonal antibodies, cell therapies, clotting factors, cytokines, enzymes, hormones and vaccines. In fact, several antibody based therapies have already been approved across the globe. Humira®, by AbbVie, is a well-known example; the drug has been generating multibillion dollar sales annually for several years.

The major challenge for biologics has been the mode of administration. For most large molecule drugs, IV is an established route. Through this method, the drug directly enters systemic circulation bypassing degradation in the gastrointestinal (GI) tract. However, there are other challenges; these include the requirement of healthcare experts for drug administration (in turn, increasing the cost of therapy) and associated pain during therapy administration (negatively impacting patient compliance).Companies developing biologics are continuously on the lookout for novel formulation and delivery systems in order to exploit their full therapeutic and commercial potential. Amongst the various aspects being studied, technologies for facilitating oral, subcutaneous (SC) and transdermal delivery of biologics are highly sought after and have received widespread attention from researchers and manufacturers across the globe.

Several start-ups, with innovative technologies, have surfaced in the past decade and have continuously encouraged the use of biotherapeutics by providing novel approaches to improve patient compliance. These technologies are broadly classified either as formulation technologies (approaches with primary objective of changing the formulation of drug, thereby facilitating an alternate route of administration in many cases) or delivery systems (approaches with primary objective of developing a physical system to deliver the drug via an alternate route).

The overall interest continues to rise as is evident from the number of partnerships / agreements that have taken place amongst the stakeholders. Technology licensing agreements have been very common and are likely to play an active role in industry's development. In addition, several venture capitalists have led multiple funding rounds in these companies, acting as a key enabler behind the evolution.

Synopsis

The 'Biotherapeutics: Novel Formulation and Delivery Approaches (Focus on Antibodies and Proteins)' report provides a comprehensive analysis of the current market landscape and the future outlook of technologies focused on the formulation and delivery of biotherapeutics, primarily proteins and antibodies. Biopharmaceuticals has become an area of heavy interest for many pharmaceutical companies; they make up about one-third of all the drugs that are currently in development. The industry is growing at a healthy pace resulting in a substantial shift from conventional chemical synthesis to biotechnological processes in the way drugs are now produced.

Intravenous (IV) route has been the most popular route for administering large molecule drugs such as proteins and antibodies. However, with the rising popularity of biologics and biosimilars, several companies are now looking forward to technologies that can be used for delivering biotherapeutics via a route other than IV injection or infusion. Technologies focused on oral, SC and transdermal routes are becoming more popular and, therefore, are expected to be the major contributors to the overall drug delivery technologies market. In addition, there are other novel targeted approaches, such as bypassing blood brain barrier, which are likely to change the industry paradigm in the long run.

During the course of our research, we identified 122 such companies that are developing either formulation technologies or novel systems for delivery of large molecule drugs. The study not only provides the list of technologies but also includes a detailed analysis on the overall market for these technologies. We have looked at the investments that have been made into these technologies and have provided detailed information of the various collaborations / licensing agreements amongst the stakeholders. This advancing trend of transition from IV to alternate delivery mechanisms highlights the crucial role of technology developers in this field.

The base year for the report is 2015. The report provides the market forecast for the period 2015-2025. The research, analysis and insights presented in this report are backed by a deep understanding,developed from both primary and secondary research, of key drivers behind the growth.

Example Highlights

  • 1. There are over 150 technologies, being developed by around 120 companies, which are focused on developing novel formulations and / or systems for delivering antibodies and proteins. Amongst the delivery systems, prime focus of the stakeholders is on oral, SC and transdermal drug delivery technologies.
  • 2. The market has attracted several start-ups; these companies, in collaboration with big pharma, are expected to foster more innovation in the near future. Some of the well-known players with proprietary technologies are (in alphabetical order) Adocia, Aegis Therapeutics, Arecor, Corium International, Cosmo Pharmaceuticals, Durect Corporation, Emisphere Technologies, Excelse Bio, Generex Biotechnology, Halozyme Therapeutics, Merrion Pharmaceuticals, Oramed Pharmaceuticals, Rani Therapeutics, Xeris Pharmaceuticals and Zosano Pharma (complete list in Chapter 4 of the report).
  • 3. These approaches focus on a wide range of mechanisms; amongst others, these include modifying the release properties along with pharmacokinetic properties, creating cold-chain free and stable liquid formulations of the drug and delivering the drugs in a targeted manner.
  • 4. Within the technologies focused on targeted delivery, there seems to be heavy focus on delivery of drugs across the Blood Brain Barrier (BBB). Delivery across the BBB has been a big challenge in case of large sized biologics. We have identified over 15 players, which aim to successfully overcome this challenge in the coming few years.
  • 5. Venture capitalists have shown an enormous amount of interest and confidence in the technology developers. In total, we traced over 200 instances of funding with the total investment amounting to an encouraging sum of USD 2.9 billion over the last decade. In addition, government agencies, such as the NIH, have also encouraged technology developers by issuing grants for a wide range of research projects.
  • 6. Driven by several factors, such as rising incidence of chronic diseases, growing popularity of biologics / biosimilars and use of delivery / formulation technologies as life cycle management tools for near patent expiry drugs, the market for such technologies is expected to grow aggressively at a healthy annual growth rate of 9.6% between 2015 and 2025.

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our study. The summary offers a high level view on the likely market evolution of the drug delivery technologies for biotherapeutics.

Chapter 3 is an introductory chapter on biotherapeutics. It includes the various advantages and challenges faced by technology developers in developing systems for delivering biotherapeutics. We have also presented, in detail, a discussion on the approved antibody therapeutics in the market, signifying the growing trend towards alternate delivery mechanisms.

Chapter 4 identifies the various approaches / technologies / systems that can be used to formulate and administer biologics. The classification system for the technologies mentioned in this chapter helps develop a deeper understanding of the market.

Chapter 5 reviewsthe key technologies available for oral delivery of biotherapeutics. We have presented profiles of several leading technologies covering information on their origin, mechanism, molecules based on these technologies and associated companies.

Chapter 6 includes profiles of key technology developers specialising in formulating and delivering biotherapeutics via the SC route. Each profile includes information such as technology overview, pipeline review, funding details and recent developments.

Chapter 7 reviews the major technologies available for transdermal/intradermal administration of biotherapeutics. Several leading companies, along with their technologies, have been profiled in this chapter. As in earlier chapters, these profiles provide an overview of the technology developers, mechanism of technologies, drugs in the pipeline based on specific technologies and associated recent developments.

Chapter 8 discusses technologies focused on other alternative administration routes (other than oral, SC and transdermal). The chapter includes key insights on technologies that alter the release kinetics and pharmacokinetics of the drug. In addition, certain technologies focused on targeted delivery, such as delivery across the blood-brain-barrier, have also been covered in this chapter.

Chapter 9 highlights the recent partnerships that have taken place in the industry. We have also discussed the various partnership models in existence and the most common forms of deals/agreements that have evolved over time.

Chapter 10 provides information on several funding instances that have driven research and development of formulation and delivery technologies for biotherapeutics. Our analysis reveals interesting insights on the growing interest of venture capitalists and other stakeholders in this market.

Chapter 11 presents a detailed ten year forecast highlighting the potential for technology developers engaged in developing technologies for delivery of biotherapeutics. Due to the uncertainty surrounding some of the key assumptions, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios. Our insights are backed by discussions with several stakeholders in the industry.

Chapter 12 provides a SWOT analysis of the drug delivery technologies market for biotherapeutics, giving strategic insights to the major factors that are likely to drive future growth whilst highlighting the weaknesses and threats that may negatively impact the industry's evolution.

Chapter 13 is a collection of transcripts of interviews conducted with key players during the course of this study.

Chapter 14 summarises the overall report. In this chapter, we provide a recap of the key takeaways and an independent future outlook based on the research and analysis described in earlier chapters.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides a list of companies and organisations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. BIOPHARMACEUTICALS: AN INTRODUCTION

  • 3.1. Background and Overview
  • 3.2. Why Biopharmaceuticals are Gaining Attention?
  • 3.3. Different Classes of Biotherapeutics
  • 3.4. Biotherapeutics That Can Benefit From Drug Delivery Advances
    • 3.4.1. Monoclonal Antibodies
    • 3.4.2. Cell Therapies
    • 3.4.3. Clotting Factors
    • 3.4.4. Cytokines
    • 3.4.5. Enzymes
    • 3.4.6. Hormones
    • 3.4.7. Vaccines
  • 3.5. Antibody Therapies
    • 3.5.1. Landscape of Approved Antibody Therapies
    • 3.5.2. Approved Antibody Therapies: Distribution by Year of Approval
    • 3.5.3. IV Infusion is the Most Common Route of Administration
    • 3.5.4. Complexities and Complications Associated with the IV Route
  • 3.6. Types of Drug Delivery Technologies
  • 3.7. Demand for Novel Drug Delivery Technologies

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Delivery Technologies for Biotherapeutics (Proteins and Antibodies)
  • 4.3. Most of the Technologies Focus on Novel Formulations
  • 4.4. Major Proportion of the Technologies Focus on Specific Route of Administration

5. KEY ORAL FORMULATIONAND DELIVERY PLATFORMS

  • 5.1. Chapter Overview
  • 5.2. Technology Licensing is the Most Popular Partnership Model
  • 5.3. Gastrointestinal Permeation Enhancement Technology (GIPET®, Merrion Pharmaceuticals)
    • 5.3.1. Overview
    • 5.3.2. Financial Information
    • 5.3.3. Patents
    • 5.3.5. Technology and Mechanism of Action
    • 5.3.6. Advantages of the Technology
    • 5.3.7. Pipeline Drugs Using GIPET®
    • 5.3.8. Agreements / Collaborations
  • 5.4. Protein Oral Delivery Technology (POD™, Oramed)
    • 5.4.1. Overview
    • 5.4.2. Financial Information
    • 5.4.3. Patents
    • 5.4.4. Technology and Mechanism of Action
    • 5.4.5. Advantages of the Technology
    • 5.4.6. Pipeline Drugs Using POD™
    • 5.4.7. Agreements / Collaborations
  • 5.5. Multi Matrix System (MMX®, Cosmo Pharmaceuticals)
    • 5.5.1. Overview
    • 5.5.2. Financial Information
    • 5.5.3. Patents
    • 5.5.4. Technology and Mechanism of Action
    • 5.5.5. Advantages of the Technology
    • 5.5.6. Pipeline Drugs Using MMX® Technology
    • 5.5.7. Agreements / Collaborations
  • 5.6. Eligen® (Emisphere Technologies)
    • 5.6.1. Overview
    • 5.6.2. Financial Information
    • 5.6.3. In-house Development of Eligen
    • 5.6.4. Technology and Mechanism of Action
    • 5.6.5. Advantages of the Technology
    • 5.6.6. Pipeline Drugs Using Eligen®
    • 5.6.7. Agreements / Collaborations
  • 5.7. RapidMist™ (Generex Biotechnology™)
    • 5.7.1. Overview
    • 5.7.2. Financial Performance
    • 5.7.3. Technology and Mechanism of Action
    • 5.7.4. Advantages of the Technology
    • 5.7.5. Pipeline Drugs Using RapidMist™
    • 5.7.6. Agreements / Collaborations
  • 5.8. Axcess™ (Proxima Concepts)
    • 5.8.1. Overview
    • 5.8.2. Patents
    • 5.8.3. Technology and Mechanism of Action
    • 5.8.4. Advantages of the Technology
    • 5.8.5. Pipeline Drugs Using Axcess™
    • 5.8.6. Agreements / Collaborations

6. KEY SUBCUTANEOUS FORMULATION AND DELIVERY PLATFORMS

  • 6.1. Chapter Overview
  • 6.2. Technology Licensing and Research Collaboration are the Two Popular Partnership Models
  • 6.3. ENHANZE™ Technology (Halozyme Therapeutics)
    • 6.3.1. Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Technology and Mechanism of Action
    • 6.3.4. Advantages of the Technology
    • 6.3.5. Pipeline Drugs Using ENHANZE™
    • 6.3.6. Agreements / Collaborations
  • 6.4. Bepo™ (MedinCell)
    • 6.4.1. Overview
    • 6.4.2. Patents
    • 6.4.3. Technology and Mechanism of Action
    • 6.4.4. Advantages of the Technology
    • 6.4.5. Pipeline Drugs Using BEPO™
    • 6.4.6. Agreements / Collaborations
  • 6.5. Medusa™ (Flamel Technologies)
    • 6.5.1. Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Technology and Mechanism of Action
    • 6.5.4. Advantages of the Technology
    • 6.5.5. Pipeline Drugs Using Medusa™
    • 6.5.6. Agreements / Collaborations
  • 6.6. XeriJect™ (Xeris Pharmaceuticals)
    • 6.6.1. Overview
    • 6.6.2. Financial Information
    • 6.6.3. Technology and Mechanism of Action
    • 6.6.4. Advantages of the Technology
    • 6.6.5. Pipeline Drugs Using XeriJect™
    • 6.6.6. Agreements / Collaborations
  • 6.7. BioChaperone® (Adocia)
    • 6.7.1. Overview
    • 6.7.2. Financial Performance
    • 6.7.3. Technology and Mechanism of Action
    • 6.7.4. Advantages of the Technology
    • 6.7.5. Pipeline Drugs Using BioChaperone®
    • 6.7.6. Agreements / Collaborations
  • 6.8. Crystalomics® Technology (Ajinomoto Althea)
    • 6.8.1. Overview
    • 6.8.2. Financial Performance
    • 6.8.3. Technology and Mechanism of Action
    • 6.8.4. Advantages of the Technology
    • 6.8.5. Pipeline Drugs Using Crystalomics®
    • 6.8.6. Agreements / Collaborations
  • 6.9. TransCon Technology (Ascendis Pharma)
    • 6.9.1. Overview
    • 6.9.2. Financial Information
    • 6.9.3. Technology and Mechanism of Action
    • 6.9.4. Advantages of the Technology
    • 6.9.5. Pipeline Drugs Using TransCon
    • 6.9.6. Agreements / Collaborations

7. KEY DERMAL FORMULATION AND DELIVERY PLATFORMS

  • 7.1. Chapter Overview
  • 7.2. Technology Licensing is the Most Common Agreement Model
  • 7.3. MicroCor® Technology (Corium International)
    • 7.3.1. Overview
    • 7.3.2. Financial Performance
    • 7.3.3. Patents
    • 7.3.4. Technology and Mechanism of Action
    • 7.3.5. Pipeline Drugs Using MicroCor®
    • 7.3.6. Agreements / Collaborations
  • 7.4. MicronJet (NanoPass Technologies)
    • 7.4.1. Overview
    • 7.4.2. Financial Information
    • 7.4.3. Technology and Mechanism of Action
    • 7.4.4. Pipeline Drugs Using MicronJet Needle
    • 7.4.5. Agreements / Collaborations
  • 7.5. ZP Patch Technology (Zosano Pharma™)
    • 7.5.1. Overview
    • 7.5.2. Financial Performance
    • 7.5.3. Technology and Mechanism of Action
    • 7.5.4. Pipeline Drugs Using ZP Patch
    • 7.5.5. Agreements / Collaborations

8. OTHER FORMULATION AND DELIVERY PLATFORMS

  • 8.1. Chapter Overview
  • 8.2. Product Development and Evaluation Agreement are Preferred Modes of Collaboration
  • 8.3. nanoZYME™, poloMAC™ and poxoMAC™ (NeuroNano Pharma)
    • 8.3.1. Overview
    • 8.3.2. nanoZYME™ Technology
    • 8.3.3. poloMAC™ and poxoMAC™ Technologies
    • 8.3.4. NeuroNano Pharma: Patent Portfolio
    • 8.3.5. Agreements / Collaborations
  • 8.4. Β-Eliminative Drug Delivery System (ProLynx)
    • 8.4.1. Overview
    • 8.4.2. Technology and Mechanism of Action
    • 8.4.3. Advantages of the Technology
    • 8.4.4. Patent Portfolio
    • 8.4.5. Agreements / Collaborations
  • 8.5. Intravail® and Aegis Hydrogels® (Aegis Therapeutics)
    • 8.5.1. Overview
    • 8.5.2. Intravail® Technology
    • 8.5.3. Aegis Hydrogels® Technology
    • 8.5.4. Agreements / Collaborations
  • 8.6. PharmFilm® Technology (MonoSol Rx)
    • 8.6.1. Overview
    • 8.6.2. Financial Performance
    • 8.6.3. Technology and Mechanism of Action
    • 8.6.4. Advantages of the Technology
    • 8.6.5. Pipeline Drugs Using PharmFilm® Technology
    • 8.6.6. Agreements / Collaborations
  • 8.7. PLEX™ Platform (PolyPid)
    • 8.7.1. Overview
    • 8.7.2. Financial Information
    • 8.7.3. Technology and Mechanism of Action
    • 8.7.4. Advantages of the Technology
    • 8.7.5. Pipeline Drugs Using PLEX™
    • 8.7.6. Agreements / Collaborations
  • 8.8. Tethadur (pSivida)
    • 8.8.1. Overview
    • 8.8.2. Financial Performance
    • 8.8.3. Technology and Mechanism of Action
    • 8.8.4. Agreements / Collaborations
  • 8.9. Phylomer® Peptides (Phylogica)
    • 8.9.1. Overview
    • 8.9.2. Financial Performance
    • 8.9.3. Technology and Mechanism of Action
    • 8.9.4. Agreements / Collaborations
  • 8.11. Transcend Technology (biOasis)
    • 8.11.1. Overview
    • 8.11.2. Financial Performance
    • 8.11.3. Technology and Mechanism of Action
    • 8.11.4. Advantages of the Technology
    • 8.11.5. Pipeline Drugs Using Transcend
    • 8.11.6. Recent Developments
    • 8.11.7. Agreements / Collaborations
  • 8.12. LRP Technology (Angiochem)
    • 8.12.1. Overview
    • 8.12.2. Financial Performance
    • 8.12.3. Technology and Mechanism of Action
    • 8.12.4. Pipeline Drugs Using LRP Technology
    • 8.12.5. Agreements / Collaborations

9. RECENT PARTNERSHIPS/COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models/Agreements
    • 9.2.1. Product Development and Commercialisation
    • 9.2.2. Technology Licensing
    • 9.2.3. Research Collaborations
    • 9.2.4. Technology Evaluation
    • 9.2.5. Product Licensing
    • 9.2.6. Manufacturing and Supply
    • 9.2.7. Clinical Trial Collaborations
    • 9.2.8. Other Agreements
  • 9.3. Collaborations Amongst the Stakeholders has Steadied
  • 9.4. Product Development and Technology Licensing are Preferred Modes of Partnership

10. VENTURE CAPITAL INTEREST

  • 10.1. Chapter Overview
  • 10.2. Instances of Funding for Focused on Formulation and Delivery of Biotherapeutics
  • 10.3. Rising Venture Capital Interest
  • 10.4. Funding Instances: Distribution by Type of Funding
  • 10.5. Leading Technology Developers: Distribution by Number of Funding Instances
  • 10.6. Most Active VC Firms/Institutions

11. MARKET FORECAST

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology
  • 11.3. Overall Drug Delivery Technologies Market, 2015-2025
  • 11.4. Subcutaneous Drug Delivery Technologies Market, 2015-2025
  • 11.5. Oral Drug Delivery Technologies Market, 2015-2025
  • 11.6. Transdermal Drug Delivery Technologies Market, 2015-2025
  • 11.7. Other Drug Delivery Technologies Market, 2015-2025

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weaknesses
  • 12.4. Opportunities
  • 12.5. Threats

13. INTERVIEW TRANSCRIPTS

  • 13.1. Interview Transcript I: Dr. Paul Ashton, President and CEO, pSivida
  • 13.2. Interview Transcript II: Tom Saylor, Non-Executive Director, Arecor
  • 13.3. Interview Transcript III: Xavier Rivero, Chief Operating Officer, Sagetis Biotech
  • 13.4. Interview Transcript IV: Rob Hutchison, biOasis, CEO & Chairman
  • 13.5. Interview Transcript V: Quinton Oswald, President and CEO, Neurotech Pharmaceuticals

14. CONCLUSION

  • 14.1. Growing Interest Across Several Stakeholders
  • 14.2. Multiple Drivers to Sustain Growth Momentum
  • 14.3. Market for Formulation and Delivery Technologies to Grow at a Healthy Rate
  • 14.4. Emergence of New Technologies
  • 14.5. Concluding Remarks

List of Figures

  • Figure 3.1 Classifications of Proteins
  • Figure 3.2 Approved Antibody Therapies: Distribution by Year of Approval
  • Figure 3.3 Approved Antibody Therapies: Distribution by Route of Administration
  • Figure 3.4 Different Types of Drug Delivery Technologies
  • Figure 3.5 Advantages of Novel Drug Delivery Technologies
  • Figure 4.1 Classification of Formulation and Delivery Technologies
  • Figure 4.2 Formulation and Delivery Technologies: Distribution by Type of Technology
  • Figure 4.3 Formulation and Delivery Technologies: Distribution by Focus of Technology
  • Figure 4.4 Formulation and Delivery Technologies: Distribution by Route of Administration
  • Figure 5.1 Oral Formulation and Drug Delivery Technologies Partnerships: Distribution by Type of Agreement
  • Figure 5.2 Merrion Pharmaceuticals: Revenues, 2012-HY2015 (USD Million)
  • Figure 5.3 Merrion Pharmaceuticals: Funding Instances (USD Million)
  • Figure 5.4 Multifunctional Role of Absorption Enhancer in GIPET®
  • Figure 5.5 Oramed: Funding Instances (USD Million)
  • Figure 5.6 Cosmo Pharmaceuticals: Revenues, 2012-HY2015 (EUR Million)
  • Figure 5.7 MMX® Technology Platform
  • Figure 5.8 Emisphere Technologies: Funding Instances (USD Million)
  • Figure 5.9 Generex Biotechnology™: Funding Instances (USD Million)
  • Figure 6.1 Subcutaneous Formulation and Drug Delivery Technologies: Distribution by Type of Agreement
  • Figure 6.2 Halozyme: Revenues, 2012-HY2015 (USD Million)
  • Figure 6.3 Halozyme Therapeutics: Funding Instances (USD Million)
  • Figure 6.4 BEPO™ Technology: Mechanism
  • Figure 6.5 Flamel Technologies: Revenues, 2012-2014 (USD Million)
  • Figure 6.6 Medusa™ Formulation Technology: Process
  • Figure 6.7 Xeris Pharmaceuticals: Funding Instances (USD Million)
  • Figure 6.8 XeriJect™ Technology: Process
  • Figure 6.9 Adocia: Revenues, 2012-HY2015 (EUR Million)
  • Figure 6.10 Adocia: Funding Instances (USD Million)
  • Figure 6.11 Ascendis Pharma: Funding Instances (USD Million)
  • Figure 7.1 Dermal Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
  • Figure 7.2 Corium: Revenues, 2012-HY2015 (USD Million)
  • Figure 7.3 Zosano Pharma: Revenues, 2013-2014 (USD Million)
  • Figure 7.4 Zosano Pharma: Funding Instances
  • Figure 8.1 Other Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
  • Figure 8.2 MonoSol Rx: Funding Instances (USD Million)
  • Figure 8.3 PolyPid: Funding Instances (USD Million)
  • Figure 8.4 pSivida: Revenues, 2012-HY2015 (USD Million)
  • Figure 8.5 biOasis: Funding Instances (USD Million)
  • Figure 8.6 Angiochem: Funding Instances (USD Million)
  • Figure 9.1 Product Development/Product Development and Commercialisation Agreements: Distribution by Focus of Technology
  • Figure 9.2 Technology Licensing Agreements: Distribution by Focus of Technology
  • Figure 9.3 Research Collaboration Agreements: Distribution by Focus of Technology
  • Figure 9.4 Technology Evaluation Agreements: Distribution by Focus of Technology
  • Figure 9.5 Product Licensing Agreements: Distribution by Focus of Technology
  • Figure 9.6 Manufacturing and Supply Agreements: Distribution by Focus of Technology
  • Figure 9.7 Clinical Trial Collaborations: Distribution by Focus of Technology
  • Figure 9.8 Other Agreements: Distribution by Focus of Technology
  • Figure 9.9 Delivery in Biotherapeutics: Year Wise Distribution of Partnership Instances
  • Figure 9.10 Collaborations: Most Active Companies
  • Figure 9.11 Collaborations: Distribution by Type of Partnership
  • Figure 10.1 Funding: Cumulative Number of Investments by Year, 1998-2015
  • Figure 10.2 Funding Instances: Distribution by Type of Funding, 1998-2015
  • Figure 10.3 Funding Instances: Distribution by Total Amount Invested, 1998-2015
  • Figure 10.4 Most Active Players: Evaluation by Number of Funding Instances, 1998-2015
  • Figure 10.5 Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)
  • Figure 10.6 Most Active VC Firms: Evaluation by Number of Funding Instances
  • Figure 11.1 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Figure 11.2 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Figure 11.3 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Figure 11.4 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Figure 11.5 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Figure 11.6 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Figure 11.7 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Figure 11.8 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Figure 11.9 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Base Scenario (USD Billion)
  • Figure 11.10 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Figure 14.1 Overall Biotherapeutics Formulation and Delivery Technologies Market: Comparative Evolution Scenarios, 2015, 2020 and 2025 (USD Billion)

List of Tables

  • Table 3.1 Difference between Small Molecule Drugs and Biologics
  • Table 3.2 List of Approved Antibody Therapies
  • Table 4.1 List of Formulation and Delivery Technologies
  • Table 5.1 Merrion Pharmaceuticals: `Patent Portfolio
  • Table 5.2 GIPET® Platforms
  • Table 5.3 GIPET®: Pipeline of Drugs
  • Table 5.4 Merrion Pharmaceuticals: Licensing/Technology Evaluation Agreements
  • Table 5.5 POD™: Patent Portfolio
  • Table 5.6 POD™: Pipeline of Drugs
  • Table 5.7 Oramed: Relevant Agreements / Collaborations
  • Table 5.8 Cosmo Pharmaceuticals: Patent Portfolio
  • Table 5.9 MMX® Technology: Pipeline of Drugs
  • Table 5.10 Cosmo Pharmaceuticals: Relevant Agreements / Collaborations
  • Table 5.11 Eligen®: Pipeline of Drugs
  • Table 5.12 Emisphere Technologies: Relevant Agreements / Collaborations
  • Table 5.13 RapidMist: Pipeline of Drugs
  • Table 5.14 Generex Biotechnology: Technology Licensing/Evaluation Agreements
  • Table 5.15 Axcess Patent Family
  • Table 5.16 Axcess™: Pipeline of Drugs
  • Table 6.1 Enhanze™: Pipeline of Drugs
  • Table 6.2 Halozyme: Technology Licensing/Evaluation Agreements
  • Table 6.3 MedinCell: Patent Portfolio
  • Table 6.4 Medusa™: Pipeline of Drugs
  • Table 6.5 XeriJect™: Pipeline of Drugs
  • Table 6.6 BioChaperone®: Pipeline of Drugs
  • Table 6.7 TransCon: Pipeline of Drugs
  • Table 7.1 MicroCor®: Pipeline of Drugs
  • Table 7.2 MicronJet Needle: Pipeline of Drugs
  • Table 7.3 NanoPass Technologies: Technology Licensing / Evaluation Agreements
  • Table 7.4 Zosano Pharma™: Product Portfolio
  • Table 7.5 Zosano Pharma: Relevant Agreements / Collaborations
  • Table 8.1 NeuroNano Pharma: Patent Portfolio
  • Table 8.2 ProLynx: Patent Portfolio
  • Table 8.3 ProLynx: Technology Licensing/Evaluation Agreements
  • Table 8.4 Aegis Therapeutics: Technology Licensing/Evaluation Agreements
  • Table 8.5 PharmFilm®: Pipeline of Drugs
  • Table 8.6 MonoSol Rx: Technology Licensing Evaluation Agreements
  • Table 8.7 PLEX: Pipeline of Drugs
  • Table 8.8 PolyPid: Relevant Agreements / Collaborations
  • Table 8.9 pSivida: Technology Licensing/Evaluation Agreements
  • Table 8.10 Phylogica: Technology Licensing/Evaluation Agreements
  • Table 8.11 biOasis: Pipeline
  • Table 8.12 biOasis Technologies: Technology Licensing/Evaluation Agreements
  • Table 8.13 LRP Technology: Pipeline of Drugs
  • Table 8.14 Angiochem: Technology Licensing/Evaluation Agreements
  • Table 9.1 Product Development/Product Development and Commercialisation Agreements, 2005 Onwards
  • Table 9.2 Technology Licensing Agreements, 2005 Onwards
  • Table 9.3 Research Collaboration Agreements, 2005 Onwards
  • Table 9.4 Technology Evaluation Agreements, 2005 Onwards
  • Table 9.5 Product Licensing Agreements, 2005 Onwards
  • Table 9.6 Manufacturing and Supply Agreements, 2005 Onwards
  • Table 9.7 Clinical Trial Collaborations, 2005 Onwards
  • Table 9.8 Other Agreements
  • Table 10.1 List of Funding Instances and Investors Involved
  • Table 10.2 Types of Funding Instances, 1998- 2015
  • Table 12.1 SWOT Analysis
  • Table 15.1 Approved Antibody Therapies: Distribution by Year of Approval
  • Table 15.2 Approved Antibody Therapies: Distribution by Route of Administration
  • Table 15.3 Formulation and Delivery Technologies: Distribution by Type of Technology
  • Table 15.4 Formulation and Delivery Technologies: Distribution based on Focus of Technology
  • Table 15.5 Formulation and Delivery Technologies: Distribution by Route of Administration
  • Table 15.6 Oral Formulation and Drug Delivery Technology Partnerships: Distribution by Type of Agreement
  • Table 15.7 Merrion Pharmaceuticals: Revenues, 2012-HY2015 (USD Million)
  • Table 15.8 Merrion Pharmaceuticals: Funding Instances (USD Million)
  • Table 15.9 Oramed: Funding Instances (USD Million)
  • Table 15.10 Cosmo Pharmaceuticals: Revenues, 2012-HY2015 (EUR Million)
  • Table 15.11 Emisphere Technologies: Funding Instances (USD Million)
  • Table 15.12 Generex Biotechnology™: Funding Instances (USD Million)
  • Table 15.13 Subcutaneous Formulation and Drug Delivery Technologies: Distribution by Type of Agreement
  • Table 15.14 Halozyme: Revenues, 2012-HY2015 (USD Million)
  • Table 15.15 Halozyme Therapeutics: Funding Instances (USD Million)
  • Table 15.16 Flamel Technologies: Revenues, 2012-2014 (USD Million)
  • Table 15.17 Xeris Pharmaceuticals: Funding Instances (USD Million)
  • Table 15.18 Adocia: Revenues, 2012-HY2015 (EUR Million)
  • Table 15.19 Adocia: Funding Instances (USD Million)
  • Table 15.20 Ascendis Pharma: Funding Instances (USD Million)
  • Table 15.21 Dermal Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
  • Table 15.22 Corium: Revenues, 2012-HY2015 (USD Million)
  • Table 15.23 Zosano Pharma: Revenues, 2013-2014 (USD Million)
  • Table 15.24 Zosano Pharma: Funding Instances
  • Table 15.25 Other Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
  • Table 15.26 MonoSol Rx: Funding Instances (USD Million)
  • Table 15.27 PolyPid: Funding Instances (USD Million)
  • Table 15.28 pSivida: Revenues, 2012-HY2015 (USD Million)
  • Table 15.29 biOasis: Funding Instances (USD Million)
  • Table 15.30 Angiochem: Funding Instances (USD Million)
  • Table 15.31 Product Development and Commercialisation Agreements: Distribution by Focus of Technology
  • Table 15.32 Technology Licensing Agreements: Distribution by Focus of Technology
  • Table 15.33 Research Collaboration Agreements: Distribution by Focus of Technology
  • Table 15.34 Technology Evaluation Agreements: Distribution by Focus of Technology
  • Table 15.35 Product Licensing Agreements: Distribution by Focus of Technology
  • Table 15.36 Manufacturing and Supply Agreements: Distribution by Focus of Technology
  • Table 15.37 Clinical Trial Collaborations: Distribution by Focus of Technology
  • Table 15.38 Other Agreements: Distribution by Focus of Technology
  • Table 15.39 Delivery in Biotherapeutics: Year Wise Distribution of Partnership Instances
  • Table 15.40 Collaborations: Distribution by Type of Partnership
  • Table 15.41 Funding: Cumulative Number of Investments by Year, 1998-2015
  • Table 15.42 Funding Instances: Distrinutoi by Type of Funding, 1998-2015
  • Table 15.43 Funding Instances: Distribution by Total Amount Invested, 1998-2015
  • Table 15.44 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
  • Table 15.45 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Table 15.46 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
  • Table 15.47 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
  • Table 15.48 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Table 15.49 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
  • Table 15.50 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
  • Table 15.51 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Table 15.52 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
  • Table 15.53 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
  • Table 15.54 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Table 15.55 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
  • Table 15.56 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
  • Table 15.57 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Table 15.58 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
  • Table 15.59 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
  • Table 15.60 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Table 15.61 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
  • Table 15.62 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
  • Table 15.63 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
  • Table 15.64 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
  • Table 15.65 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
  • Table 15.66 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Table 15.67 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
  • Table 15.68 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Conservative Scenario (USD Billion)
  • Table 15.69 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Base Scenario (USD Billion)
  • Table 15.70 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Optimistic Scenario (USD Billion)
  • Table 15.71 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
  • Table 15.72 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
  • Table 15.73 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
  • Table 15.74 Overall Biotherapeutics Formulation and Delivery Technologies Market: Comparative Evolution Scenarios, 2015, 2020 and 2025 (USD Billion)

List of Companies

  • Following companies have been mentioned in this report.
  • 1. 4P Therapeutics
  • 2. AbbVie
  • 3. ADOCIA
  • 4. Advanced Accelerator Applications
  • 5. Aegis Therapeutics
  • 6. Aerogen
  • 7. Affilogic
  • 8. Affinity Therapeutics
  • 9. Agila Specialities
  • 10. AIMM Therapeutics
  • 11. Albany Medical College
  • 12. Alchemia
  • 13. Alcyone
  • 14. Allergan
  • 15. Alrise Biosystems
  • 16. Althea
  • 17. Amarantus BioSciences
  • 18. AmatsiSEPS
  • 19. Angiochem
  • 20. Aphios
  • 21. Applied Molecular Transport
  • 22. Apricus Biosciences
  • 23. Aquarius Biotechnologies (Acquired by Matinas Biopharma)
  • 24. Aradigm
  • 25. Aratana Therapeutics
  • 26. Arecor
  • 27. ArmaGen
  • 28. Arsenal Medical
  • 29. Asahi Kasei Pharma
  • 30. Ascendis Pharma
  • 31. AstraZeneca
  • 32. Axela Biosensors
  • 33. Battelle
  • 34. Baxter
  • 35. Bayer Healthcare
  • 36. biOasis Technologies
  • 37. BioCardia
  • 38. Biodel
  • 39. BioLingus
  • 40. BrainsGate
  • 41. Caleva Process Solutions
  • 42. Camarus AB
  • 43. CannScience Innovations
  • 44. Capsugel
  • 45. Carbylan Therapeutics
  • 46. Carlina Technologies
  • 47. CarThera
  • 48. Catalent Pharma
  • 49. CellProThera
  • 50. Chiasma Pharmaceuticals
  • 51. Circassia Pharmaceuticals
  • 52. Corium International
  • 53. Cosmo Pharmaceuticals
  • 54. CrossLink Bioscience
  • 55. Cubist Pharmaceuticals
  • 56. Dainippon Sumitomo
  • 57. Delpor
  • 58. DelSiTech
  • 59. DNAtrix
  • 60. DNX
  • 61. Dr. Reddy's
  • 62. Durect Corporation
  • 63. Dynamic Microbials
  • 64. Eisai
  • 65. Ekteino
  • 66. Elcam Medical
  • 67. Eli Lilly
  • 68. Emisphere
  • 69. Encap
  • 70. Endo International
  • 71. Entrega Bio
  • 72. ETI Karle Clinical
  • 73. ExcelseBio
  • 74. Extend Biotechnology
  • 75. Ferring Pharmaceuticals
  • 76. Flamel Technologies
  • 77. FluGen
  • 78. Galena Biopharma
  • 79. GALVmed
  • 80. GenBiotech
  • 81. Genentech
  • 82. Generex Biotechnology
  • 83. Generium
  • 84. Genta
  • 85. Genzyme
  • 86. Geron
  • 87. GlaxoSmithKline
  • 88. Graybug
  • 89. GSK
  • 90. H Lundbeck
  • 91. Halozyme Therapeutics
  • 92. Hikma Pharmaceuticals
  • 93. Hospira
  • 94. Hovione
  • 95. ICB International
  • 96. Innocore
  • 97. Intarcia Therapeutics
  • 98. Integrated Animal Health
  • 99. Intranasal Technology Inc (ITI)
  • 100. Intrexon
  • 101. Janssen Pharmaceuticals
  • 102. JCR Pharmaceuticals
  • 103. Johnson and Johnson
  • 104. JRX Biotechnology
  • 105. Kaer Therapeutics
  • 106. KemPharm
  • 107. Kereos
  • 108. Kurve Technology
  • 109. Kytogenics Pharmaceuticals
  • 110. Landec
  • 111. Laser Detect Systems
  • 112. Latitude Pharmaceuticals
  • 113. Lauren Sciences
  • 114. Le Métier de Beauté
  • 115. Leukocare Biotechnology
  • 116. Lipotek
  • 117. Liquidia Technologies/ Envisia Therapeutics
  • 118. Lung Rx
  • 119. Lysogene
  • 120. Medallion Therapeutics
  • 121. Medicure
  • 122. MedImmune
  • 123. MedinCell
  • 124. Medpace
  • 125. Merck
  • 126. Merrion Pharmaceuticals
  • 127. Midatech Group
  • 128. MIS Dental Implants Technologies
  • 129. Monosol Rx
  • 130. Mountain View Pharmaceuticals
  • 131. MSD Animal Health
  • 132. Mylan
  • 133. Nano Precision Medical
  • 134. Nanomerics
  • 135. NanoPass Technologies
  • 136. Nanovector
  • 137. NeuroNano
  • 138. Neurotech
  • 139. NHTherapeutics
  • 140. NOD Pharmaceuticals
  • 141. Novartis
  • 142. Novo Nordisk
  • 143. Oakwood Laboratories
  • 144. Octoplus
  • 145. Ocular Therapeutix
  • 146. Opsona Therapeutics
  • 147. Oramed Pharmaceuticals
  • 148. Orbis Biosciences
  • 149. Orion Pharma
  • 150. Pacira Pharmaceuticals
  • 151. Pantec Biosolutions
  • 152. PATH
  • 153. Patheon
  • 154. PCI Biotech
  • 155. Pearl Therapeutics
  • 156. Peptineo
  • 157. Permeon Biologics
  • 158. Pfizer
  • 159. Pharmidex
  • 160. PhaseBio Pharmaceuticals
  • 161. Phosphagenics
  • 162. Phylogica
  • 163. PolyPid
  • 164. ProCore Bio Med
  • 165. ProLynx
  • 166. Prometheon Pharma
  • 167. Protheragen
  • 168. Proxima Concepts
  • 169. pSivida
  • 170. Pulmatrix
  • 171. Rani Therapeutics
  • 172. Roche
  • 173. Ruthigen
  • 174. Sagetis Biotech
  • 175. Sanofi
  • 176. Sanofi Aventis
  • 177. Santen
  • 178. Scil Proteins
  • 179. Serina Therapeutics
  • 180. Servier
  • 181. Shire
  • 182. Smoofi
  • 183. Solvanix
  • 184. Stallergenes
  • 185. Sterigenics
  • 186. Strativa Pharmaceuticals
  • 187. Suda
  • 188. Swiss Caps AG
  • 189. Symphony Medical
  • 190. Synthelis
  • 191. Takeda Pharmaceuticals
  • 192. Tamarisk Technologies Group
  • 193. Targeted Cell Therapies
  • 194. TheraKine
  • 195. Tibotec
  • 196. Transdermal Corp.
  • 197. Transdermal Specialties
  • 198. UCB
  • 199. UCL
  • 200. Valerion Therapeutics
  • 201. Valeritas
  • 202. Vaxxas
  • 203. Vect-Horus
  • 204. Vectura
  • 205. Vestiq Pharmaceuticals
  • 206. Wacker Biotech
  • 207. Wyeth Pharmaceuticals
  • 208. Xenetic Biosciences
  • 209. Xenios AG
  • 210. Xeris Pharmaceuticals
  • 211. XL Protein GmbH
  • 212. XstalBio
  • 213. YEDA
  • 214. Zogenix
  • 215. Zosano Pharma

Following VC Firms have been mentioned in the report

  • 1. 5AM Ventures
  • 2. 7 Med Health Ventures
  • 3. Abingworth
  • 4. Advanced Technology Ventures
  • 5. Aegis Capital Corp
  • 6. AGF Private Equity
  • 7. Alpes Developpement Durable Investissement
  • 8. Alpha Associates
  • 9. Alta Partners
  • 10. Altitude Life Sciences Ventures
  • 11. AnGes MG
  • 12. Apax Partners
  • 13. Aphelion Capital
  • 14. ARCH Venture Partners
  • 15. Ascension Health Ventures
  • 16. Astellas Venture Management
  • 17. Atlas Venture
  • 18. Avida Group
  • 19. BDC Capital
  • 20. Beacon Angels
  • 21. Beta Fund
  • 22. Bill & Melinda Gates Foundation
  • 23. Bioam Gestion
  • 24. BioMed Ventures
  • 25. Boehringer Ingelheim Venture Fund
  • 26. Boston Harbor Angels
  • 27. Brandon Capital
  • 28. Broadfin Capital
  • 29. Burrill and Company
  • 30. Business Development Bank of Canada
  • 31. Canaan Partners
  • 32. Capital Royalty
  • 33. Capital Royalty Partners II
  • 34. CDC Enterprises
  • 35. Central Texas Angel Network
  • 36. Chase H&Q
  • 37. Cherrystone Angel Group
  • 38. Chicago Growth Partners
  • 39. CHL Medical Partners
  • 40. Clarus Ventures
  • 41. CNF Investments
  • 42. Covington Capital
  • 43. Crystal Horizon Investments
  • 44. Deerfield Management
  • 45. Deutsche Banc Alex. Brown
  • 46. DNA Biomedical Solutions Ltd.
  • 47. Domain Associates
  • 48. DSM Venturing
  • 49. Edward P. Bass group
  • 50. Essex Woodlands Health Ventures
  • 51. F2 Capital
  • 52. F2 Ventures
  • 53. F3 Ventures
  • 54. Firelake Capital Management
  • 55. Fletcher Spaght Ventures
  • 56. Fredric Price
  • 57. Glide Healthcare Partners
  • 58. Golden Seeds
  • 59. Google Ventures
  • 60. Granite State Angels
  • 61. Hambrecht & Quist
  • 62. Harbor Light Capital Partners
  • 63. Harkness & Hill
  • 64. Hatteras Venture Partners
  • 65. HBM BioVentures
  • 66. Health Ventures
  • 67. HealthCare Venture
  • 68. Hercules Technology Growth Capital
  • 69. HLM Venture Partners
  • 70. Hygea VCT Plc
  • 71. Idinvest Partners
  • 72. InCube Ventures
  • 73. InterSouth Partners
  • 74. InterWest Partners
  • 75. Investment Accelerator Fund-Life Sciences
  • 76. Israel HealthCare Ventures
  • 77. J&J Development Corporation
  • 78. Jerusalem Global Ventures
  • 79. Kaiser Permanante Ventures
  • 80. Kingsbridge Capital
  • 81. Ladenburg Thalmann & Co.
  • 82. LaunchPad Venture Group
  • 83. Life Science Angels
  • 84. LifeCare Partners
  • 85. Maryland Venture Fund
  • 86. Mass Medical Angels
  • 87. Maxim Group LLC
  • 88. Mayflower
  • 89. Medical Research Commercialisation Fund
  • 90. Merlin Biosciences
  • 91. MHR Funding Management
  • 92. Mitsui & Co. Global Investment
  • 93. Montaur Capital Partners
  • 94. Morningside Group
  • 95. MPM Capital
  • 96. New Enterprise Associates
  • 97. New Leaf Ventures
  • 98. New River Management V
  • 99. Nexus Medical Partners
  • 100. Nomura International
  • 101. Nomura Phase4 Ventures
  • 102. North Bridge Venture Partners
  • 103. North Country Angels
  • 104. Northland Securities
  • 105. Novartis Venture Fund
  • 106. Ofer Hi-Tech
  • 107. Omega Fund
  • 108. OneVentures
  • 109. ONSET Ventures
  • 110. OrbiMed Advisors
  • 111. OSI Pharmaceuticals
  • 112. Oxford Finance
  • 113. Oxford Finance Corporation
  • 114. Pacific Venture Opportunity Fund
  • 115. Pappas Ventures
  • 116. Pharmsynthez
  • 117. Pinemount Investment
  • 118. Pitango Venture Capital
  • 119. Polaris Partners
  • 120. Polaris Venture Partners
  • 121. Pound Capital
  • 122. ProQuest Investments
  • 123. Province of Nova Scotia
  • 124. Quantum Technology Partners
  • 125. RA Capital Management
  • 126. Rhône-Alpes Création
  • 127. Rock Springs Capital
  • 128. Rodman & Renshaw, Ladenburg Thalmann & Co.
  • 129. Savoy
  • 130. Scale Venture Partners
  • 131. SG Asset Management Private Equity
  • 132. Siemens Venture Capital
  • 133. Silicon Valley Bank
  • 134. Sofinnova Partners
  • 135. SofInnova Ventures
  • 136. Sparta LLC
  • 137. Sud Rhone-Alpes Capital
  • 138. SV Life Sciences
  • 139. Takeda Ventures
  • 140. Tech Coast Angels
  • 141. TechnoStart
  • 142. Texas Venture Labs
  • 143. The Halifax Group
  • 144. The Stevanato Group
  • 145. Think Equity Partners
  • 146. Thomas McNerney & Partners
  • 147. Vatera Healthcare Partners
  • 148. Venrock
  • 149. Venture Health
  • 150. Versant Ventures
  • 151. VG Partners
  • 152. Viaduct
  • 153. Viveris Management
  • 154. Vivo Capital
  • 155. Vivo Ventures
  • 156. Wakefield Group
  • 157. Warburg Dillon Read LLC, and Adams
  • 158. WBB Securities
  • 159. Welsh, Carson, Anderson & Stowe
  • 160. Western Life Sciences Venture Fund
  • 161. White Oak Global Advisors
  • 162. WR Hambrecht + Co
  • 163. Wuzhou Zhongheng Group
  • 164. Xenia Ventures
  • 165. Yissum Research Development

Following Institutes / Universities / Organisations have been mentioned in this report.

  • 1. National Institute of Diabetes and Digestive and Kidney Disease
  • 2. National Institute of Mental Health
  • 3. National Institute of Standards and Technology
  • 4. Bispebjerg University Hospital
  • 5. Brigham and Women's Hospital
  • 6. Exeter University
  • 7. Infectious Disease Research Institute
  • 8. Laboratory for Drug Delivery (Georgia Institute of Technology)
  • 9. The School of Pharmacy, University of London
  • 10. Technical University Munich (TUM)
  • 11. University of Cambridge
Back to Top